Daniel Teper

Greater New York City Area, NY United States

CEO at IMMUNE Pharmaceuticals

Medical / Health Care / Pharmaceuticals

Founder and CEO of IMMUNE Pharmaceuticals, Grew into a NASDAQ listed company in 3 years. IMMUNE focuses on Antibody Therapeutics with a lead phase II first in class mAb, bertilimumab, for the treatment of inflammatory diseases, including Crohn's and Colitis and Bullous Pemphigoid, an auto-immune orphan disease of the skin. Pipeline includes Amiket, a drug with Orphan Drug Designation for the treatment of Post Herpetic Neurlalgia. Immune is seeking a development and commercialization partner for Amiket. Immune NanomAb platform, developed with the Hebrew University of Jerusalem, is the next generation of "guided therapeutic missiles" targeting specifically cancer cells through a three step ...